Astrotech Corporation — Form 10-K summary
Period: Fiscal year ended June 30, 2021, filed September 21, 2021. The request metadata says “2019 Q4,” but the supplied filing is Astrotech’s FY2021 annual report, not a 2019 quarterly filing.
Business context and reporting period
Astrotech develops and commercializes mass spectrometry technology through subsidiaries: 1st Detect (security trace detectors), AgLAB (hemp and cannabis processing instruments), and BreathTech (breath-based screening under development). ATI owns and licenses the core technology. The company reported three segments; BreathTech’s results are included in ATI.
1st Detect’s TRACER 1000 had European Civil Aviation Conference certification and was deployed at 14 locations in nine countries as of the filing. U.S. TSA cargo detection testing remained in progress. AgLAB had launched its AgLAB-1000-D2 product; BreathTest-1000 was still in development.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $334,000 | $488,000 |
| Gross profit / margin | $36,000 / 11% | $39,000 / 8% |
| Operating expenses | $7.946 million | $8.153 million |
| Operating loss | $7.910 million | $8.114 million |
| Net loss | $7.603 million | $8.311 million |
| Basic and diluted loss per share | $0.35 | $1.31 |
| Cash used in operating activities | $7.410 million | $6.931 million |
| Cash and cash equivalents at year-end | $35.936 million | $3.349 million |
At June 30, 2021, short-term investments were $27.351 million, total current assets $65.110 million, current liabilities $4.211 million, and working capital approximately $60.9 million. Total assets were $65.633 million and total liabilities $4.426 million.
Financing activities provided $67.582 million, primarily from equity offerings; investing activities used $27.585 million, largely to purchase short-term investments. The balance sheet reported $2.5 million in related-party term debt, secured and accruing interest at 11% annually. The $542,000 PPP loan was forgiven in April 2021. In a subsequent September 2021 transaction, the company paid the 2020 note in full and paid $1.0 million of principal on the 2019 note; the remaining 2019 note maturity was extended to September 5, 2022.
Changes versus the prior year
- Revenue fell 32%, mainly because pandemic-related microchip delays constrained TRACER 1000 deliveries. Substantially all revenue in both years came from TRACER sales to DHL in FY2020 and two material sources/customers in FY2021.
- Gross margin improved from 8% to 11%, while gross profit declined slightly. Management expects margins to benefit from higher production volumes and product refinements.
- Operating expenses declined 3%; R&D expense fell 22% to $2.692 million as the company reduced headcount and shifted toward commercialization.
- Net loss narrowed by $708,000, including a $542,000 PPP forgiveness gain. Results also included $513,000 of corporate-lease disposal expense.
- Equity issuance generated $67.6 million net proceeds. The company issued approximately 39.6 million shares during FY2021; weighted-average shares increased from 6.346 million to 21.984 million. It also issued warrants covering approximately 2.3 million shares.
Outlook, commentary, risks, and unusual items
- Management said the equity financings resolved the prior-year substantial doubt about the company’s ability to continue as a going concern. No quantified revenue, earnings, or cash-flow guidance was provided.
- Commercial execution remains dependent on regulatory milestones: TSA cargo detection testing and U.S. approval for TRACER 1000 were unfinished. BreathTest-1000’s FDA classification was undetermined; the company had not submitted an EUA request and disclosed that it had not yet performed clinical testing of the device.
- COVID-19 and supply constraints delayed TSA testing, customer activity, and production; the company also cited worldwide microchip shortages. Further delays, customer payment disruption, or renewed pandemic impacts could affect operations and liquidity.
- Revenue is highly concentrated, the business units have limited operating histories and limited revenue, and the company has incurred substantial cumulative losses. The accumulated deficit was $207.4 million.
- A stockholder class action and derivative suit challenged the validity of a 2020 certificate amendment. The company disputed the allegations and sought court validation. A later-approved increase in authorized common shares, from 50 million to 250 million, had not been filed pending resolution of the validation proceeding.
- The CEO was also a lender: the year-end $2.5 million term debt was secured and carried an 11% rate. The September 2021 repayment and extension are subsequent events, not year-end balance-sheet changes.
- The company terminated its former Austin office lease and allowed its Webster facility lease to expire, consolidating operations in Austin and engaging Sanmina for manufacturing. Management estimated approximately $870,000 in net cash savings from the office lease termination; a separate business discussion cited estimated savings of $1.2 million over the original lease term.
- The financial statements received an unqualified audit opinion. Management concluded internal controls were effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Progress, timing, and outcome of TSA cargo detection testing and any U.S. Air Cargo Screening Technology List approval.
- TRACER 1000 order conversions, deliveries, recurring service revenue, customer concentration, and the effect of component shortages.
- BreathTest-1000 clinical, FDA classification, and EUA or other regulatory milestones; commercial prospects for AgLAB products.
- Actual cash burn and investment liquidity relative to commercialization spending, and the status and terms of the remaining CEO-related note.
- Share authorization and court proceedings, plus potential dilution from issued shares, warrants, preferred stock, and equity compensation awards.